Highlights in myasthenia gravis from AANEM 2024 include efficacy data on efgartigimod, ravulizumab, zilucoplan, and first-in-class inebilizumab, as well as safety outcomes in pregnancy for eculizumab.
On September 30, the Anti-Defamation League (ADL) hosted the “Antisemitism 101” workshop in the Dining Center as part of Haverford’s Meeting the Moment initiative announced earlier ...